AUTHOR AND EDITOR INFORMATION

Section 1 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

INTRODUCTION

Section 2 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Background

Of the estimated 17,000 primary brain tumors diagnosed in the United States each year, approximately 60% are gliomas. Gliomas comprise a heterogeneous group of neoplasms that differ in location within the CNS, in age and sex distribution, in growth potential, in extent of invasiveness, in morphological features, in tendency for progression, and in response to treatments.

Glioblastoma multiforme (GBM) is by far the most common and most malignant of the glial tumors. Composed of a heterogenous mixture of poorly differentiated neoplastic astrocytes, glioblastomas primarily affect adults, and they are located preferentially in the cerebral hemispheres. Much less commonly, GBMs can affect the brain stem in children and the spinal cord. These tumors may develop from lower-grade astrocytomas (World Health Organization [WHO] grade II) or anaplastic astrocytomas (WHO grade III), but, more frequently, they manifest de novo, without any evidence of a less malignant precursor lesion. The treatment of glioblastomas is palliative and includes surgery, radiotherapy, and chemotherapy.

Pathophysiology

Glioblastomas can be classified as primary or secondary. Primary GBMs account for the vast majority of cases (60%) in adults older than 50 years. When these tumors manifest de novo (ie, without clinical or histopathologic evidence of a preexisting, less-malignant precursor lesion), they present after a short clinical history, usually less than 3 months.

Secondary GBMs (40%) typically develop in younger patients ( <45 y) through malignant progression from a low-grade astrocytoma (WHO grade II) or anaplastic astrocytoma (WHO grade III). The time required for this progression varies considerably, ranging from less than 1 year to more than 10 years, the mean interval being 4-5 years. Increasing evidence indicates that primary and secondary glioblastomas constitute distinct disease entities that evolve through different genetic pathways, affect patients at different ages, and differ in response to some of the present therapies. Of all the astrocytic neoplasms, glioblastomas contain the greatest number of genetic changes, which, in most cases, result from the accumulation of multiple mutations.

Over the past decade, the concept of different genetic pathways leading to the common phenotypic endpoint (ie, GBM) has gained general acceptance. Genetically, primary and secondary glioblastomas show little overlap and constitute different disease entities. Studies are beginning to assess the prognoses associated with different mutations. Some of the more common genetic abnormalities are described as follows:

• Loss of heterozygosity (LOH): LOH on chromosome arm 10q is the most frequent gene alteration for both primary and secondary glioblastomas, occurring in 60-90% of cases. This mutation appears to be specific for GBM and is found rarely in other tumor grades. This mutation is associated with poor survival. LOH at 10q plus 1 or 2 of the additional gene mutations appear to be frequent alterations and are most likely major players in the development of glioblastomas.
• p53: Mutations in p53, a tumor suppressor gene, were among the first genetic alterations identified in astrocytic brain tumors. Deletion or alteration of the p53 gene appears to be present in approximately 25-40% of all GBMs. The p53 immunoreactivity also appears to be associated with tumors that arise in younger patients.
• Epidermal growth factor receptor (EGFR) gene: The EGFR gene is involved in the control of cell proliferation. Multiple genetic mutations are apparent, including both overexpression of the receptor as well as rearrangements that result in truncated isoforms. However, all the clinically relevant mutations appear to contain the same phenotype leading to increased activity. These tumors typically show a simultaneous loss of chromosome 10 but rarely a concurrent p53 mutation.
• MDM2: Amplification or overexpression of MDM2 constitutes an alternative mechanism to escape from p53-regulated control of cell growth by binding to p53 and blunting its activity. Overexpression of MDM2 is the second most common gene mutation in GBMs and is observed in 10-15% of patients. Some studies show that this mutation has been associated with a poor prognosis.
• Platelet-derived growth factor–alpha (PDGF-alpha) gene: The PDGF gene acts as a major mitogen for glial cells by binding to the PDGF receptor (PDGFR). Amplification or overexpression of PDGFR is typical (60%) in the pathway leading to secondary glioblastomas.
• PTEN: PTEN (also known as MMAC and TEP1) encodes a tyrosine phosphatase located at band 10q23.3. The function of PTEN as a cellular phosphatase, turning off signaling pathways, is consistent with possible tumor-suppression action. When phosphatase activity is lost because of genetic mutation, signaling pathways can become activated constitutively, resulting in aberrant proliferation. PTEN mutations have been found in as many as 30% of glioblastomas.

Less frequent but more malignant mutations include the following:

• MMAC1-E1 - A gene involved in the progression of gliomas to their most malignant form
• MAGE-E1 - A glioma-specific member of the MAGE family that is expressed at up to 15-fold higher levels in GBMs than in normal astrocytes
• NRP/B - A nuclear-restricted protein/brain, which is expressed in neurons but not in astrocytes (NRP/B mutants are found in glioblastoma cells.)

Additional genetic alterations in primary glioblastomas include p16 deletions (30-40%), p16INK4A and retinoblastoma (RB) gene protein alterations. Progression of secondary glioblastomas often includes LOH at chromosome arm 19q (50%), RB protein alterations (25%), PTEN mutations (5%), deleted-in-colorectal-carcinoma gene (DCC) gene loss of expression (50%), and LOH at 10q (see Image 1).

GBMs occur most often in the subcortical white matter of the cerebral hemispheres. In a series of 987 glioblastomas from University Hospital Zurich, the most frequently affected sites were the temporal (31%), parietal (24%), frontal (23%), and occipital (16%) lobes. Combined frontotemporal location is particularly typical. Tumor infiltration often extends into the adjacent cortex or the basal ganglia. When a tumor in the frontal cortex spreads across the corpus callosum into the contralateral hemisphere, it creates the appearance of a bilateral symmetric lesion, hence the term butterfly glioma. Sites for glioblastomas that are much less common are the brainstem (which often is found in affected children), the cerebellum, and the spinal cord.

Frequency

International

GBM is the most frequent primary brain tumor, accounting for approximately 12-15% of all intracranial neoplasms and 50-60% of all astrocytic tumors. In most European and North American countries, incidence is approximately 2-3 new cases per 100,000 people per year.

Mortality/Morbidity

No significant advancements in the treatment of glioblastoma have occurred in the past 25 years. Although current therapies remain palliative, they have been shown to prolong quality survival. Mean survival is inversely correlated with age, which may reflect exclusion of older patients from clinical trials. Without therapy, patients with GBMs uniformly die within 3 months. Patients treated with optimal therapy, including surgical resection, radiation therapy, and chemotherapy, have a median survival of approximately 12 months, with fewer than 25% of patients surviving up to 2 years and fewer than 10% of patients surviving up to 5 years. Whether the prognosis of patients with secondary glioblastoma is better than or similar to those patients with primary glioblastoma remains controversial.

Sex

In a review of 1003 glioblastoma biopsies from the University Hospital Zurich, males had a slight preponderance over females, with a ratio of 3:2.

Age

GBM may manifest at any age, but it affects adults preferentially, with a peak incidence at 45-70 years. In the series from University Hospital Zurich (a review of 1003 glioblastoma biopsies), 70% of patients were in this age group, with a mean age of 53 years. In a series reported by Dohrman (1976), only 8.8% of GBMs occurred in children.¹

CLINICAL

Section 3 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

History

The clinical history of patients with glioblastoma multiformes (GBMs) usually is short, spanning less than 3 months in more than 50% of patients, unless the neoplasm developed from a lower-grade astrocytoma.

• The most common presentation of patients with glioblastomas is a slowly progressive neurologic deficit, usually motor weakness. However, the most common symptom experienced by patients is headache.
• Alternatively, patients may present with generalized symptoms of increased intracranial pressure, including headaches, nausea and vomiting, and cognitive impairment.
• Seizures are another common presenting symptom.

Physical

Neurologic symptoms and signs affecting patients with glioblastomas can be either general or focal and reflect the location of the tumor.

• General symptoms include headaches, nausea and vomiting, personality changes, and slowing of cognitive function.
• • Headaches can vary in intensity and quality, and they frequently are more severe in the early morning or upon first awakening.
  • Changes in personality, mood, mental capacity, and concentration can be early indicators or may be the only abnormalities observed.
• Focal signs include hemiparesis, sensory loss, visual loss, aphasia, and others.
• Seizures are a presenting symptom in approximately 20% of patients with supratentorial brain tumors.

Causes

Aside from the rare occurrence of familial brain tumors (eg, neurofibromatosis 1 or 2), which constitute less than 1% of all the patients with gliomas, the etiology of gliomas remains unknown.

DIFFERENTIALS

Section 4 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Other Problems to be Considered

Anaplastic astrocytoma
Cavernous malformation
Cerebral abscess
CNS lymphoma
Encephalitis
Intracranial hemorrhage
Metastasis
Oligodendroglioma

WORKUP

Section 5 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Lab Studies

• Currently, no specific laboratory studies are helpful in making a diagnosis of glioblastoma.
• Response to adjuvant therapy may be predicted by the tumor's genetics.

Imaging Studies

• Imaging studies of the brain are essential to make the diagnosis of GBM.
• On CT scans, glioblastomas usually appear as irregularly shaped hypodense lesions with a peripheral ringlike zone of contrast enhancement and a penumbra of cerebral edema (see Image 2).
• MRI with and without contrast is the study of choice. These lesions typically have an enhancing ring observed on T1-weighted images (see Images 3-6) and a broad surrounding zone of edema apparent on T2-weighted images (see Images 7-8). The central hypodense core represents necrosis, the contrast-enhancing ring is composed of highly dense neoplastic cells with abnormal vessels permeable to contrast agents, and the peripheral zone of nonenhancing low attenuation is vasogenic edema containing varying numbers of invasive tumor cells. Several pathological studies have clearly shown that the area of enhancement does not represent the outer tumor border because infiltrating glioma cells can be identified easily within, and occasionally beyond, a 2-cm margin.
• Positron emission tomography (PET) scans and magnetic resonance (MR) spectroscopy can be helpful to identify glioblastomas in difficult cases, such as those associated with radiation necrosis or hemorrhage. On PET scans, increased regional glucose metabolism closely correlates with cellularity and reduced survival. MR spectroscopy demonstrates an increase in the choline-to-creatine peak ratio, an increased lactate peak, and decreased N-acetylaspartate (NAA) peak in areas with glioblastomas.
• Cerebral angiograms are not necessary for the diagnosis or clinical management of glioblastomas.

Other Tests

• Electroencephalography (EEG) performed on a patient with a GBM may show generalized diffuse slowing and/or epileptogenic spikes over the area of the tumor. However, findings specific for glioblastoma cannot be observed on EEG.

Procedures

• Lumbar puncture generally is contraindicated in the setting of a brain tumor because of the possibility of transtentorial herniation with increased intracranial pressure. However, if ruling out lymphoma, it may be necessary.
• CSF studies do not aid significantly in the specific diagnosis of GBM.

Histologic Findings

As its name suggests, the histopathology of GBM is extremely variable. GBMs are composed of poorly differentiated, often pleomorphic astrocytic cells with marked nuclear atypia and brisk mitotic activity. Necrosis is an essential diagnostic feature, and prominent microvascular proliferation is common. Macroscopically, glioblastomas are poorly delineated, with peripheral grayish tumor cells, central yellowish necrosis from myelin breakdown, and multiple areas of old and recent hemorrhages. Most glioblastomas of the cerebral hemispheres are clearly intraparenchymal with an epicenter in the white matter, but some extend superficially and contact the leptomeninges and dura.

Despite the short duration of symptoms, these tumors often are surprisingly large at the time of presentation, occupying much of a cerebral lobe. Undoubtedly, glial fibrillary acidic protein (GFAP) remains the most valuable marker for neoplastic astrocytes. Although immunostaining is variable and tends to decrease with progressive dedifferentiation, many cells remain immunopositive for GFAP even in the most aggressive glioblastomas. Vimentin and fibronectin expression are common but less specific.

The regional heterogeneity of glioblastomas is remarkable and makes histopathological diagnosis a serious challenge when it is based solely on stereotactic needle biopsies. Tumor heterogeneity also is likely to play a significant role in explaining the meager success of all treatment modalities, including radiation, chemotherapy, and immunotherapy.

Staging

Completely staging most glioblastomas is neither practical nor possible because these tumors do not have clearly defined margins. Rather, they exhibit well-known tendencies to invade locally and spread along compact white matter pathways, such as the corpus callosum, internal capsule, optic radiation, anterior commissure, fornix, and subependymal regions. Such spread may create the appearance of multiple glioblastomas or multicentric gliomas on imaging studies.

Careful histological analyses have indicated that only 2-7% of glioblastomas are truly multiple independent tumors rather than distant spread from a primary site. Despite its rapid infiltrative growth, the glioblastoma tends not to invade the subarachnoid space and, consequently, rarely metastasizes via CSF. Hematogenous spread to extraneural tissues is very rare in patients who have not had previous surgical intervention, and penetration of the dura, venous sinuses, and bone is exceptional.

TREATMENT

Section 6 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Medical Care

The treatment of glioblastomas remains difficult in that no contemporary treatments are curative. While overall mortality rates remain high, recent work leading to an understanding of the molecular mechanisms and gene mutations combined with clinical trials are leading to more promising and tailored therapeutic approaches. Multiple challenges remain, including tumor heterogeneity, tumor location in a region where it is beyond the reach of local control, and rapid, aggressive tumor relapse. Therefore, the treatment of patients with malignant gliomas still remains palliative and encompasses surgery, radiotherapy, and chemotherapy.

• Radiation therapy
• • Radiation therapy in addition to surgery or surgery combined with chemotherapy has been shown to prolong survival in patients with GBMs compared to surgery alone.
  • Dose response relationships for glioblastomas demonstrate that a radiation dose of less than 4500 cGy results in a median survival of 13 weeks compared with a median survival of 42 weeks with a dose of 6000 cGy.
  • The responsiveness of GBMs to radiotherapy varies. In many instances, radiotherapy can induce a phase of remission, often marked with stability or regression of neurologic deficits as well as diminution in the size of the contrast-enhancing mass. Unfortunately, any period of response is short-lived because the tumor typically recurs within 1 year, resulting in further clinical deterioration and the appearance of an expansile region of contrast enhancement.
  • Two studies investigated tumor recurrence after whole-brain radiation therapy and found that the tumor recurred within 2 cm of the original site in 90% and 78% of patients, supporting the use of focal radiation therapy. Multifocal recurrence occurred in 6% of patients in one study and in 5% of patients in a second trial.
  • Interstitial brachytherapy delivers a large dose of radiation to the tumor volume, with rapid fall-off of radiation in surrounding tissue. The tumor must be unilateral and smaller than 5 cm in diameter. In one study, patients treated with interstitial brachytherapy had a significantly better median survival (2 mo) compared with the conventional focal external beam radiation therapy. Following interstitial brachytherapy, up to 40% of patients will require another surgery for removal of tissue damaged by radiation necrosis.
  • Experimental studies are underway in which focal radiation is delivered directly to tumors through an implanted balloon containing interstitial radiation. MRI and MR spectroscopy can be used to monitor therapy. Clinical outcomes from these studies are not yet available.
  • Radiosensitizers are compounds that increase the therapeutic effect of radiation therapy. At this time, only motexafin gadolinium, a metallotexaphyrin, has been shown to increase time-to-progression when combined with radiotherapy in a phase III trial of brain metastases.
• Chemotherapy - Antineoplastics
• • Although the optimal chemotherapeutic regimen for glioblastoma is not defined at present, several studies have suggested that more than 25% of patients obtain a significant survival benefit from adjuvant chemotherapy.
  • Temozolomide is an orally active alkylating agent that is used for newly diagnosed with GBM. It was approved by the United States Food and Drug Administration (FDA) in March 2005. Studies have shown that the drug was well-tolerated and provided a survival benefit. Temozolomide with radiation was associated with significant improvements in median progression-free survival (6.9 vs 5 mo), overall survival (14.6 vs 12.1 mo), and the likelihood of being alive in 2 years (26% vs 10%).
  • Nitrosoureas: BCNU-polymer wafers (Gliadel wafers) were approved by the FDA in 2002. A phase III randomized trial that included 240 patients compared surgery with implantation of polymer wafers with BCNU into the tumor bed demonstrated significant prolongation of survival compared with a placebo wafer. Both groups received radiation therapy. The median survival was 13.9 months in the group treated with Gliadel wafers and 11.6 months in the group treated with placebo. This increase in survival appears to be at the expense of predominantly hematologic side effects.
  • Carmustine (BCNU) and cis-platinum (cisplatin) have been the primary chemotherapeutic agents used against malignant gliomas. All agents in use have no greater than a 30-40% response rate, and most fall into the range of 10-20%.
• • Data from the University of California at San Francisco indicate that, for the treatment of glioblastomas, surgery followed by radiation therapy leads to 1-, 3-, and 5-year survival rates of 44%, 6%, and 0%, respectively. By comparison, surgery followed by radiation and chemotherapy using nitrosourea-based regimens resulted in 1-, 3-, and 5-year survival rates of 46%, 18%, and 18%, respectively.
  • A major hindrance to the use of chemotherapeutic agents for brain tumors is the fact that the blood-brain barrier (BBB) effectively excludes many agents from the CNS. For this reason, novel methods of intracranial drug delivery are being developed to deliver higher concentrations of chemotherapeutic agents to the tumor cells while avoiding the adverse systemic effects of these medications.
  • Pressure-driven infusion of chemotherapeutic agents through an intracranial catheter, also known as clysis, has the advantage of delivering drugs along a pressure gradient rather than by simple diffusion. Clysis has shown promising results in animal models with agents including BCNU and topotecan.
  • Initial attempts investigated the delivery of chemotherapeutic agents via an intraarterial route rather than intravenously. Unfortunately, no survival advantage was observed.
  • Genotyping of brain tumors may have applications in stratifying patients for clinical trials of various novel therapies.
  • A small proportion of glioblastomas responds to gefitinib or erlotinib (tyrosine kinase inhibitors). The simultaneous presence in glioblastoma cells of mutant EGFR (EGFRviii) and PTEN was associated with responsiveness to tyrosine kinase inhibitors.

Surgical Care

The extent of surgery (biopsy vs resection) has been shown in a number of studies to affect length of survival. In a study by Ammirati and colleagues (1987), patients with high-grade gliomas who had a gross total resection had a 2-year survival rate of 19%, while those with a subtotal resection had a 2-year survival rate of 0%.²

Because these tumors cannot be cured with surgery, the surgical goals are to establish a pathological diagnosis, relieve mass effect, and, if possible, achieve a gross total resection to facilitate adjuvant therapy. Most glioblastomas recur in and around the original tumor bed, but contralateral and distant recurrences are not uncommon, especially with lesions near the corpus callosum. The indications for reoperation of malignant astrocytomas after initial treatment with surgery, radiation therapy, and chemotherapy are not firmly established. Reoperation generally is considered in the face of a life-threatening recurrent mass, particularly if radionecrosis rather than recurrent tumor is suspected as the cause of clinical and radiographic deterioration.

Although no formal studies have been performed, observations indicate that variables, such as young age, prolonged interval between operations, and extent of the second surgical resection, have prognostic significance. PET scans and MR spectroscopy have proven useful in discriminating between these 2 entities (see Images 1-8). The median survival for anaplastic astrocytoma after reoperation in 3 series varied from 56-88 weeks.

Stereotactic biopsy followed by radiation therapy may be considered in certain circumstances. These include patients with a tumor located in an eloquent area of the brain; patients whose tumors have minimal mass effect or are infiltrating without discrete margins; and patients in poor medical condition, precluding general anesthesia. Median survival after stereotactic biopsy and radiation therapy is reported to be from 27-47 weeks.

Consultations

Patients with glioblastomas should be evaluated by a team of specialists, including a neurologist, neurosurgeon, neurooncologist, and radiation oncologist, in order to develop a coordinated treatment strategy.

Diet

No dietary restrictions are necessary.

Activity

No universal restrictions on activity are necessary for patients with glioblastomas. The patient's activity depends on his or her overall neurologic status. The presence of seizures may prevent the patient from driving. In many circumstances, physical therapy and/or rehabilitation are extremely beneficial. Activity is encouraged to reduce the risk of deep venous thrombosis.

MEDICATION

Section 7 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

No specific medications exist to treat glioblastomas. However, certain conditions require medical treatment. For seizures, the patient usually is started on phenytoin (Dilantin) or carbamazepine (Tegretol). Vasogenic cerebral edema typically is managed with corticosteroids (eg, dexamethasone), usually in combination with some form of antiulcer agent (eg, famotidine, ranitidine). The American Academy of Neurology's practice parameters state that prophylactic antiepileptic drugs (AEDs) should not be administered routinely to patients with newly diagnosed brain tumors (standard) and should be discontinued in the first postoperative week in patients who have not experienced a seizure.

Drug Category: Anticonvulsants

These agents are used to treat and prevent seizures.

Drug Category: Corticosteroids

These agents reduce edema around the tumor, frequently leading to symptomatic and objective improvement.

Drug Category: Antineoplastic agents

Although the optimal chemotherapeutic regimen for glioblastoma is not yet defined, several studies have suggested significant survival benefit from adjuvant chemotherapy.

FOLLOW-UP

Section 8 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Further Inpatient Care

• Patients with glioblastomas who undergo surgical resection typically spend the night after surgery in an intensive care unit, followed by an inpatient stay of 3-5 days. The final length of stay depends on each patient's neurological condition.
• Postoperative antibiotics usually are continued for 24 hours, and deep vein thrombosis prophylaxis is continued until patients are ambulatory.
• Anticonvulsants are maintained at therapeutic levels throughout the inpatient stay, while steroids are reduced gradually, tailored to each patient's clinical status.
• Many patients benefit from occupational therapy and physical therapy or rehabilitation.
• While patients are in the hospital, they should receive postoperative imaging to determine the extent of surgical resection. Surgical resection is evaluated best within 3 days of surgery by using contrast-enhanced MRI. Contrast enhancement during this period accurately reflects residual tumor.
• If not performed preoperatively, complete evaluations by consulting physicians, including a neurooncologist and radiation oncologist, should be considered postoperatively.

In/Out Patient Meds

• Patients usually are maintained on anticonvulsant medications, and levels are checked intermittently.
• Steroids are tapered to lower doses for radiation therapy and then tapered further if possible. While taking steroids, patients should be maintained on an antiulcer agent.

Transfer

• At some institutions, transferring the patient to another facility may be necessary if the proper consultations cannot be obtained.
• In most cases, surgical resection can be performed on an urgent, but not emergent, basis.

Complications

• Brain tumor resection has an overall mortality rate of 1-2%.
• Approximately 40% of patients have no or minimal deficits after surgery, 30% manifest no postoperative change relative to preoperative deficits, and 25% sustain an increased postoperative deficit that usually improves.

Prognosis

• Despite extensive clinical trials, individual prediction of clinical outcome has remained an elusive goal. Glioblastomas are among the most malignant human neoplasms, with a median survival despite optimal treatment of less than 1 year. In a series of 279 patients receiving aggressive radiation and chemotherapy, only 5 of 279 patients (1.8%) survived longer than 3 years.³
• Patient survival depends on a variety of clinical parameters. Younger age, higher Karnofsky performance (a standard measure of the ability of patients with cancer to perform daily tasks) score at presentation, radiotherapy, and chemotherapy all correlate with improved outcome. Clinical evidence also suggests that a greater extent of resection favors longer survival.
• Survival has not been shown to correlate with p53, EGFR, or MDM2 mutations.
• Long-term survivors, defined as those who survive longer than 2 years, are rare.
• Clearly, new approaches for the management of glioblastomas are necessary. Enrollment of patients into clinical trials will generate new information regarding investigational therapies. Novel approaches, such as the use of gene therapy and immunotherapy, as well as improved methods for the delivery of antiproliferative, antiangiogenic, and noninvasive therapies, provide hope for the future.

Patient Education

For excellent patient education resources, visit eMedicine's Cancer and Tumors Center. Also, see eMedicine's patient education article Brain Cancer.

MISCELLANEOUS

Section 9 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Medical/Legal Pitfalls

Because glioblastoma can be a devastating disease, meaningful communication between the physician and the patient and family is of paramount importance. To avoid medical legal pitfalls, including the patient's family in discussions regarding clinical management is essential. This often prevents family members from developing unrealistic expectations. Furthermore, communication among all the team members, including the neurosurgeon, neurologist, neurooncologist, and radiation oncologist, is important to ensure that the patient and family receive a unified treatment plan.

MULTIMEDIA

Section 10 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Media file 1:  Genetic pathways elucidated in the evolution of primary and secondary glioblastoma.
	View Full Size Image
Media type:  Graph

Media file 2:  Axial CT scan without intravenous contrast. This image reveals a large right temporal intraaxial mass (glioblastoma multiforme [GBM]). Extensive surrounding edema is present, as demonstrated by the peritumoral hypodensity, and a moderate right-to-left midline shift can be noted. Images 2-8 are radiologic studies of the same patient.
	View Full Size Image
Media type:  CT

Media file 3:  A T1-weighted axial MRI without intravenous contrast. This image demonstrates a hemorrhagic multicentric tumor (glioblastoma multiforme [GBM]) in the right temporal lobe. Effacement of the ventricular system is present on the right, and mild impingement of the right medial temporal lobe can be observed on the midbrain.
	View Full Size Image
Media type:  MRI

Media file 4:  A T1-weighted axial MRI with intravenous contrast. Heterogenous enhancement of the lesion is present within the right temporal lobe. The hypointensity circumscribed within the enhancement is suggestive of necrosis. This radiologic appearance is typical of a multicentric glioblastoma multiforme (GBM).
	View Full Size Image
Media type:  MRI

Media file 5:  A T1-weighted coronal MRI with intravenous contrast. This image demonstrates the lesion (glioblastoma multiforme [GBM]) within the medial temporal lobe and the stereotypical pattern of contrast enhancement.
	View Full Size Image
Media type:  MRI

Media file 6:  A T1-weighted sagittal MRI with intravenous contrast in a patient with glioblastoma multiforme (GBM).
	View Full Size Image
Media type:  MRI

Media file 7:  A T2-weighted axial MRI. The tumor (glioblastoma multiforme [GBM]) and surrounding white matter within the right temporal lobe show increased signal intensity compared to a healthy brain, suggesting extensive tumorigenic edema.
	View Full Size Image
Media type:  MRI

Media file 8:  A fluid-attenuated inversion recovery (FLAIR) axial MRI. This image is similar to the T2-weighted image (see Image 7) and demonstrates extensive edema in a patient with glioblastoma multiforme (GBM).
	View Full Size Image
Media type:  MRI

Media file 9:  Histopathologic slide demonstrating a glioblastoma multiforme (GBM).
	View Full Size Image
Media type:  Image

Media file 10:  Magnetic resonance (MR) spectroscopy is representative of a glioblastoma multiforme (GBM).
	View Full Size Image
Media type:  Image

REFERENCES

Section 11 of 11

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

1. Dohrmann GJ, Farwell JR, Flannery JT. Glioblastoma multiforme in children. J Neurosurg. Apr 1976;44(4):442-8. [Medline].
2. Ammirati M, Vick N, Liao YL, et al. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery. Aug 1987;21(2):201-6. [Medline].
3. Scott JN, Rewcastle NB, Brasher PM, et al. Long-term glioblastoma multiforme survivors: a population-based study. Can J Neurol Sci. Aug 1998;25(3):197-201. [Medline].
4. Barker FG, Prados MD, Chang SM, et al. Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg. Mar 1996;84(3):442-8. [Medline].
5. Barnard RO, Geddes JF. The incidence of multifocal cerebral gliomas. A histologic study of large hemisphere sections. Cancer. Oct 1 1987;60(7):1519-31. [Medline].
6. Batzdorf U, Malamud N. The Problem of Multicentric Gliomas. J Neurosurg. Feb 1963;20:122-36. [Medline].
7. Black PM. Brain tumor. Part 2. N Engl J Med. May 30 1991;324(22):1555-64. [Medline].
8. Black PM. Brain tumors. Part 1. N Engl J Med. May 23 1991;324(21):1471-6. [Medline].
9. Bouvier-Labit C, Chinot O, Ochi C, et al. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol. Oct 1998;24(5):381-8. [Medline].
10. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. Apr 22 1995;345(8956):1008-12. [Medline].
11. Bruce JN, Falavigna A, Johnson JP, et al. Intracerebral clysis in a rat glioma model. Neurosurgery. Mar 2000;46(3):683-91. [Medline].
12. Bullard DE, Bigner DD. Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors. J Neurosurg. Jul 1985;63(1):2-16. [Medline].
13. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer. May 1 1987;59(9):1617-25. [Medline].
14. Burger PC, Heinz ER, Shibata T, Kleihues P. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg. May 1988;68(5):698-704. [Medline].
15. Burger PC, Scheithauer BW. Tumors of the central nervous system. In: Atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology; 1994.
16. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer. Sep 1 1985;56(5):1106-11. [Medline].
17. Caccamo DV, Rubenstein LJ. Tumors: Applications of immunohistochemical methods. In: Neuropathology: The diagnostic approach. St Louis, Mo: Mosby-Year Book; 1997:193-218.
18. Chamberlain MC, Kormanik PA. Practical guidelines for the treatment of malignant gliomas. West J Med. Feb 1998;168(2):114-20. [Medline].
19. Ciric I, Rovin R, Cozzens JW. Role of surgery in the treatment of malignant cerebral gliomas. In: Malignant Cerebral Glioma. Park Ridge, Ill: American Association of Neurological Surgeons; 1990:141-53.
20. Coffey RJ, Lunsford LD, Taylor FH. Survival after stereotactic biopsy of malignant gliomas. Neurosurgery. Mar 1988;22(3):465-73. [Medline].
21. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer. Nov 15 1988;62(10):2152-65. [Medline].
22. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg. May 1993;78(5):767-75. [Medline].
23. Dropcho EJ, Soong SJ. The prognostic impact of prior low grade histology in patients with anaplastic gliomas: a case-control study. Neurology. Sep 1996;47(3):684-90. [Medline].
24. Duerr EM, Rollbrocker B, Hayashi Y, et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene. Apr 30 1998;16(17):2259-64. [Medline].
25. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A. May 15 1992;89(10):4309-13. [Medline].
26. Fadul C, Wood J, Thaler H, et al. Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology. Sep 1988;38(9):1374-9. [Medline].
27. Giordana MT, Bradac GB, Pagni CA, et al. Primary diffuse leptomeningeal gliomatosis with anaplastic features. Acta Neurochir (Wien). 1995;132(1-3):154-9. [Medline].
28. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. May 23 2000;54(10):1886-93. [Medline].
29. Glantz MJ, Hoffman JM, Coleman RE, et al. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol. Apr 1991;29(4):347-55. [Medline].
30. Greenberg MS. Tumor: Primary brain tumors. In: Handbook of Neurosurgery. 4^th ed. Lakeland, Fla: Greenberg Graphics; 1997:244-311.
31. Halperin EC, Bruger PC. Conventional external beam radiotherapy for central nervous system malignancies. In: Frank BD, ed. Symposium on Neuro-Oncology. Vol 3. 4^th ed. New York, NY: Neurologic Clinics; 1985:867-82.
32. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. Mar 10 2005;352(10):997-1003. [Full Text].
33. Herholz K, Pietrzyk U, Voges J, et al. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg. Dec 1993;79(6):853-8. [Medline].
34. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology. Sep 1980;30(9):907-11. [Medline].
35. Hoffman HJ, Duffner PK. Extraneural metastases of central nervous system tumors. Cancer. Oct 1 1985;56(7 Suppl):1778-82. [Medline].
36. Hulbanni S, Goodman PA. Glioblastoma multiforme with extraneural metastases in the absence of previous surgery. Cancer. Mar 1976;37(3):1577-83. [Medline].
37. Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I, Bruce JN. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery. Dec 2000;47(6):1391-8; discussion 1398-9. [Medline].
38. Kim TS, Halliday AL, Hedley-Whyte ET, Convery K. Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg. Jan 1991;74(1):27-37. [Medline].
39. Kleihues P, Burger PC, Cavenee WK. Glioblastoma. In: WHO Classification: Pathology and genetics of tumors of the nervous system. ed. Lyon, France: International Agency for Research on Cancers; 1997:16-24.
40. Korkolopoulou P, Christodoulou P, Kouzelis K, et al. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer. 1997;75(9):1269-78. [Medline].
41. Kornblith PL. The role of cytotoxic chemotherapy in the treatment of malignant brain tumors. Surg Neurol. Dec 1995;44(6):551-2. [Medline].
42. Kornblith PL, Walker M. Chemotherapy for malignant gliomas [published erratum appears in J Neurosurg 1988 Oct;69(4):645]. J Neurosurg. Jan 1988;68(1):1-17. [Medline].
43. Lampl Y, Eshel Y, Gilad R, Sarova-Pinchas I. Glioblastoma multiforme with bone metastase and cauda equina syndrome. J Neurooncol. Apr 1990;8(2):167-72. [Medline].
44. Lang FF, Miller DC, Koslow M, Newcomb EW. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg. Sep 1994;81(3):427-36. [Medline].
45. Lantos PL, VandenBerg SR, Kleihues P. Tumors of the nervous system. In: Graham DI, Lantos PL, eds. Greenfield's Neuropathology. 6^th ed. London, England: Edward Arnold; 1998:583-879.
46. Leibel SA, Scott CB, Loeffler JS. Contemporary approaches to the treatment of malignant gliomas with radiation therapy. Semin Oncol. Apr 1994;21(2):198-219. [Medline].
47. Lesser GJ, Grossman S. The chemotherapy of high-grade astrocytomas. Semin Oncol. Apr 1994;21(2):220-35. [Medline].
48. Levin VA. Chemotherapy of primary brain tumors. In: Frank BD, ed. Symposium on Neuro-Oncology. Vol 3. 4^th ed. New York, NY: Neurologic Clinics; 1985:855-66.
49. Levin VA, Silver P, Hannigan J, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. Feb 1990;18(2):321-4. [Medline].
50. Liang BC, Thornton AF, Sandler HM, Greenberg HS. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg. Oct 1991;75(4):559-63. [Medline].
51. Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. Jan 10-18 1985;313(5998):144-7. [Medline].
52. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. Jul 1990;8(7):1277-80. [Medline].
53. Mahaley MS, Mettlin C, Natarajan N, et al. National survey of patterns of care for brain-tumor patients. J Neurosurg. Dec 1989;71(6):826-36. [Medline].
54. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. Nov 10 2005;353(19):2012-24. [Full Text].
55. Nagashima G, Suzuki R, Hokaku H, et al. Graphic analysis of microscopic tumor cell infiltration, proliferative potential, and vascular endothelial growth factor expression in an autopsy brain with glioblastoma. Surg Neurol. Mar 1999;51(3):292-9. [Medline].
56. Newcomb EW, Cohen H, Lee SR, et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol. Oct 1998;8(4):655-67. [Medline].
57. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. Dec 7 1989;342(6250):705-8. [Medline].
58. Ohgaki H, Watanabe K, Peraud A, et al. A case history of glioma progression. Acta Neuropathol (Berl). May 1999;97(5):525-32. [Medline].
59. Pasquier B, Pasquier D, N'Golet A, et al. Extraneural metastases of astrocytomas and glioblastomas: clinicopathological study of two cases and review of literature. Cancer. Jan 1 1980;45(1):112-25. [Medline].
60. Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg. Jun 1985;62(6):816-22. [Medline].
61. Pedersen PH, Rucklidge GJ, Mork SJ, et al. Leptomeningeal tissue: a barrier against brain tumor cell invasion. J Natl Cancer Inst. Nov 2 1994;86(21):1593-9. [Medline].
62. Pompili A, Calvosa F, Caroli F, et al. The transdural extension of gliomas. J Neurooncol. Jan 1993;15(1):67-74. [Medline].
63. Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: (125)I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys. Mar 1 2004;58(3):972-5. [Medline].
64. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov. May 2004;3(5):430-46. [Full Text].
65. Rich JN, Hans C, Jones B, et al. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. May 15 2005;65(10):4051-8. [Medline]. [Full Text].
66. Rich JN, Rasheed BK, Yan H. EGFR mutations and sensitivity to gefitinib. N Engl J Med. Sep 16 2004;351(12):1260-1; author reply 1260-1. [Medline].
67. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma.&nb